Table 4.
Subgroup analysis of patients with daily urine protein < 1.73 g
| Group 1, Aggressive treatment (N = 45) |
Group2, Supportive treatment (N = 10) |
P value | |
|---|---|---|---|
| Age at biopsy | 50.2 [40.5–58.7] | 50.9 [46.9–63.9] | 0.294 |
| Creatinine (mg/dL) | 1.8 [1.4–2.4] | 1.7 [1.5–2.3] | 0.768 |
| eGFR (ml/min/1.73m2) | 33.2 [23.8–48.1] | 30.9 [22.5–46.7] | 0.751 |
| Proteinuria (g/d) | 0.3 [0.2–0.6] | 0.5 [0.3–0.8] | 0.111 |
| Regimen | |||
| CsA based | 10 (22.2%) | 3 (30.0%) | |
| FK-506 based | 35 (77.8%) | 7 (70.0%) | |
| Drug level | |||
| CsA (ng/ml) | 90.6 [86.4–115.0] | 88.3 [84.2–96.5] | 0.637 |
| FK-506 (ng/ml) | 5.3 [4.3–6.2] | 5.2 [3.9–6.8] | 0.959 |
| Banff score | |||
| cg | 1.0 [0.0–1.0] | 1.0 [0.0–1.0] | 0.683 |
| ci + ct | 2.0 [0.0–2.0] | 2.0 [2.0–2.0] | 0.269 |
| mm | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 0.943 |
| g + ptc | 3.0 [2.0–4.0] | 3.0 [2.0–3.0] | 0.445 |
cg transplant glomerulopathy, ci interstitial fibrosis, ct tubular atrophy, mm mesangial matrix increase, g glomerulitis, ptc peritubular capillary inflammation